Immuvac (MIP)

Vaccine Platform

Mycobacterial – Inactivated

Phase of Development

Phase 3

Candidate Overview

Sponsor / Lead Developer: Indian Council of Medical Research

Development partner(s): Cadila Pharmaceuticals

Primary Indication: Prevention of TB disease

Target Population(s): Adolescents and Adults

Clinical Trials

ACTIVE TRIALS
Registry NumberCTRI/2019/01/017026
Clinical Trial PhasePhase 3
StatusActive
Primary endpoint(s) for this clinical trialPrevention of active TB disease
Target population(s) for clinical trialAdults
Adolescents